Deadline: 29-May-24
The European Commission (EC) is seeking applications to reduce time-to-market and foster the development of new AI-based healthcare products and services that significantly improve patient safety and wellbeing, while preserving privacy and security.
This action is not only relevant to the implementation of the EHDS, but also to the implementation of the Artificial Intelligence Act (AIA)14, which establishes an overarching framework for trustworthy AI, including in healthcare (e.g. medical devices).
Objectives
- Healthcare demands continue to increase due to factors like population growth, aging populations, and the prevalence of chronic diseases. Healthcare technologies can help meet these demands by, among others, increasing effectiveness of treatment and diagnostic solutions and efficiency of health systems. The deployment of new medical digital technologies and artificial intelligence (AI) powered solutions for healthcare purposes requires access to real world health data. The amount of data available to drive the development of AI should be as large as possible to limit the introduction of biases that could undermine the effectiveness and safety of healthcare AI solutions or increase inequalities in access to care.
- The European Health Data Space (EHDS) establishes a common framework for the reuse of health data. It aims to facilitate and streamline access to EU-wide real-world health data for specific purposes such as the development, testing, deployment and uptake of products or services contributing to public health or the training, testing and evaluation of algorithms, including in medical devices, AI systems and digital health applications. The proposal for a Regulation on the EHDS10213 provides for Health Data Access Bodies (HDABs) in each country as trusted anchors to support and supervise the reuse of health data.
- As part of the wider AI ecosystem in health, such as Testing and Experimentation Facilities (TEFs) for AI and European Digital Innovation Hubs (EDIHs), this action aims to strengthen the role and capabilities of HDABs in streamlining the testing and deployment pathways for healthcare AI solutions.
Scope
- The action comprises the following:
- Identifying current pathways, i.e. regulatory, organisational and technical processes and means, for the development, testing and deployment of AI in health, as well as limitations, bottlenecks and gaps reducing the overall effectiveness of these pathways;
- Designing more effective pathways by leveraging EHDS and Health Data Access Bodies, and possibly Testing and Experimentation Facilities (TEFs) and European Digital Innovation Hubs (EDIHs);
- Creating and implementing the necessary capabilities at the level of the Health Data Access Bodies to support these pathways for the development, testing and deployment of AI in health, and building around them an appropriate community including where appropriate, data users, data holders, TEFs and EDIHs;
- Testing and showcasing these pathways with Health Data Access Bodies and the relevant actors in the community, based on specific examples in relevant disease areas, e.g. cancer, mental health or cardiovascular diseases;
- Providing guidelines and recommendations for improving the development, testing and deployment pathways for AI in health, taking advantage of the opportunities offered by the EHDS.
Funding Information
- EUR 4 000 000 per project.
- Duration: 36 months.
Outcomes and Deliverables
- Report on the identified pathways for testing and deployment of AI in health and their limitations and gaps in the current landscape;
- Description of pathways based on health data access bodies’ services and other key actors such as TEFs and EDIHs, where relevant, in light of the EHDS and the AIA;
- Guidelines for creating and deploying the necessary capabilities for HDABs to support the development, testing and deployment pathways for AI in healthcare;
- Reports on the tests and showcases conducted;
- Recommendations for the implementing of development, testing and deployment pathways of AI in health based on the opportunities offered by the EHDS and the requirements of the AIA.
KPIs to measure Outcomes and Deliverables
- Number of Health Data Access Bodies (HDABs) offering operationalised pathways for testing and deployment of AI in health [target: at least 3 HDABs in 3 different MS by the end of the project]
- Number of tests and showcases conducted of pathways for testing and deployment of AI in health [target: at least 1 test/showcase for HDAB by the end of the project]
- Number of data access applications related to AI processed by HDABs [target: at least 2 applications per pathway by the end of the project]
- Number of HDABs engaged in implementing the pathways for testing and deployment of AI in health [target: at least 10 HDABs by the end of the project]
Targeted Stakeholders
- Health data access bodies, public sector bodies and Member States’ authorities; academia; healthcare providers; private entities such as health technology SMEs and start-ups.
- In addition to the eligibility criteria on consortium composition, the consortium is highly encouraged to include at least 3 Health Data Access Bodies from 3 different eligible countries, and 3 companies/institutes/developers/innovators developing AI solutions from 3 different eligible countries.
Eligibility Criteria
- Only the following countries are eligible: EU Member States, EEA countries and countries associated to the Digital Europe Programme. Entities must not be directly or indirectly controlled from a country that is not an eligible country unless the granting authority agrees to allow for exceptional participation on the basis of a guarantee.
For more information, visit European Commission.